Acutus Medical (NSDQ:AFIB) announced that it appointed Dr. Steven Mickelsen as its chief translational science officer.

Carlsbad, Calif.-base Acutus, which develops cardiac mapping technology, said in a news release that Mickelsen is set to guide the company’s vision to deliver the “most advanced electrophysiology therapeutic solutions on the market for physicians and their patients.”

Mickelsen is slated to advance Acutus’ commitment to innovation across its access, diagnostic and therapy product portfolios, including furthering research and development for gold-tip catheter technology for use in pulsed-field ablation and radiofrequency ablation.

“The field of arrhythmia science is evolving at a breakneck speed,” Mickelsen said in the release. “Physicians want to provide the best possible care, but we’re often confined by the limitations of technology. Acutus is changing that, and this is an opportunity to play a critical role delivering advanced EP solutions to treat the entire spectrum of cardiac arrhythmias. Pulsed-field ablation represents an exciting potential future for EP; I’m thrilled to join a team that is dedicated to creating new solutions and enhancing the possibilities for physicians and their patients.”

Mickelsen previously practiced as a cardiac electrophysiologist at the University of Iowa Hospitals and Clinics in Iowa City. He also founded Farapulse, a company seeking to discover more effective treatments for Afib, in 2012. He served as its president, CEO and chief scientific officer before stepping down in 2016 to focus on clinical research.

“Acutus is committed to creating game-changing solutions and establishing new standards of care for cardiac arrhythmia management,” Acutus president & CEO Vince Burgess said. “Dr. Mickelsen’s clinical and technical expertise and unique history pioneering the development of breakthrough therapeutic medical devices is indispensable as we progress from research to commercialization of important technologies such as pulsed-field ablation.”